Press Releases
Launch of high-quality (pre-clinical) enzymes suitable for pre-clinical and process development in mRNA vaccine and therapeutics
Saint-Germain-en-Laye, France –September 12, 2023 – Life Science Newswire - Takara Bio Europe (TBE) announced today the launch of new High Quality (HQ) grade mRNA production enzymes “T7 RNA polymerase, HQ” and "Pyrophosphatase (inorganic), HQ" suitable for pre-clinical and process development in mRNA vaccine and therapeutic manufacturing.
HQ grade enzymes have features more similar to GMP grade quality (e.g. the same set of quality tests as GMP grade, see details below) than RUO grade enzymes, facilitating a smooth transition to GMP-grade manufacturing. Additionally, the high volume format (1 mL/tube) offers convenience for scaling up processes.
We are expanding our lineup of HQ enzymes to support pre-clinical and process development stages in mRNA production, including another HQ grade product "Recombinant RNase Inhibitor, HQ", set to be launched soon. We also plan to sequentially provide GMP grade enzymes suitable for active pharmaceutical ingredients for manufacturing mRNA vaccines and therapeutic drugs.
About Takara Bio
Takara Bio is a renowned supplier of high-quality life science products to support various areas of research, including genomics, molecular and cellular biology. Our portfolio includes products such as PCR reagents, cloning systems including the In-fusion seamless cloning system, vaccine development, pathogen detection, gene expression and viral vector tools and kits, and protein purification reagents. With an extensive range of research and GMP-grade products, Takara Bio caters to the diverse needs of researchers in academia, industry, and clinical settings with its. Takara Bio's products are designed to enable reliable, accurate, and efficient research across a range of applications, making them essential tools for cutting-edge research in the life sciences.
In addition, Takara Bio. serves as a one-stop CDMO providing a wide range of mRNA vaccine and therapeutic development, manufacturing, and quality testing services with the aim of enhancing the reach of mRNA as a novel modality. For more information, please click here.
